An abuse deterrent and misuse deterrent transdermal patch comprising aversive agents incorporated in the backing layer of the patch. The aversive agents can exhibit biphasic or sustained kinetics of release with an immediate portion released rapidly and an extended portion released in a prolonged manner when exposed to a dissolution medium. The prolonged aversive agent release provides deterrence against extraction of drug from fresh and used patches and serves to prevent accidental misuse of used patches by children. The abuse deterrent and misuse deterrent patch systems can be used for transdermal delivery of therapeutically active agents and particularly those drugs that are highly prone to abuse such as opiate and opioid analgesics and stimulants.

A Transdermal Drug Delivery System (TDDS) of the reservoir or plaster type for administrating clobazam for the treatment of various types of anxiety and epilepsy, for 1 day, 2 day, 3 day, 4 day, 5 day, 6 day and/or 7-day continuous application.

A biological tissue transdermal patch houses a battery part and an active ingredient such that they do not come into contact with each other. For the use of the biological tissue transdermal patch, the battery part and the active ingredient are brought into contact to start battery reaction of the battery part and the battery part is attached to a biological tissue. Carbonized bacterial cellulose or cellulose nanofiber carbon is used for a positive electrode of the battery part.

A transdermal therapeutic system which is free of fibrous constituents, and a method for the production of such a transdermal therapeutic system A preparation containing active substance is applied by a printing method onto the pressure-sensitive adhesive layer of the transdermal therapeutic system.

The potential for substance abuse involving residual amounts of abusable substances remaining in used skin-worn patches is reduced by the provision of a system and method for combining the abusable substance with a separate anti-abuse substance agent as part of a removal or disposal procedure.

An abuse deterrent and misuse deterrent transdermal patch comprising aversive agents incorporated in the backing layer of the patch. The aversive agents can exhibit biphasic or sustained kinetics of release with an immediate portion released rapidly and an extended portion released in a prolonged manner when exposed to a dissolution medium. The prolonged aversive agent release provides deterrence against extraction of drug from fresh and used patches and serves to prevent accidental misuse of used patches by children. The abuse deterrent and misuse deterrent patch systems can be used for transdermal delivery of therapeutically active agents and particularly those drugs that are highly prone to abuse such as opiate and opioid analgesics and stimulants.

An adhesive patch for securing a transdermal device to the skin comprises a double-sided adhesive layer. A permeable membrane element is located in an aperture in the adhesive layer. There is a small area of overlap where the adhesive layer adheres to the membrane element to secure it against movement during application and use of the patch.

A package that is suitable for packaging an article for collecting or administering a pharmaceutical active substance is disclosed. The package includes a first packaging component that includes a product-contacting sealant layer that includes a first ethylene vinyl alcohol copolymer. The package includes a second packaging component that includes a product-contacting sealant layer that includes a second ethylene vinyl alcohol copolymer. The ethylene content of the second ethylene vinyl alcohol copolymer is equal to or less than about 38 percent and the ethylene content of the first ethylene vinyl alcohol copolymer is greater than the ethylene content of the second ethylene vinyl alcohol copolymer.

A transdermal film formulation containing transfersomes incorporated onto the transdermal film is provided. The transfersomes include avanafil, a phospholipid, and an edge activator, wherein the phospholipid to avanafil ratio is from 3.5:1 to 4.5:1 and wherein the edge activator has a hydrophilic-lipophilic (HLB) value of 2-4. Methods of making the transdermal film formulation and methods of delivering avanafil using the transdermal film formulation are also provided.

There is provided a plastic material comprising at least one cannabinoid embedded within a structural polymer, wherein the plastic material is formulated to exude the at least one cannabinoid through an outer surface of the plastic material at a therapeutically effective rate for a period of at least a week or at least a month. The plastic material may comprise a liquid-absorbent material embedded within the structural polymer and a carrier oil absorbed into the liquid-absorbent material, wherein at least one cannabinoid is dissolved in the carrier oil.